{"entity":{"id":"nct05086692","kind":"trial","name":"A Beta-only IL-2 ImmunoTherapY Study","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab in renal cell carcinoma and non-small-cell lung cancer, run by Medicenna Therapeutics, Inc., now recruiting.","summary":"A Beta-only IL-2 ImmunoTherapY Study is a phase 1/2 interventional study registered as NCT05086692 by Medicenna Therapeutics, Inc., with 115 participants planned, started 2021-08-27 and due to reach its primary completion in 2026-06-30. Interventions recorded: MDNA11, Pembrolizumab (KEYTRUDA®). Conditions listed: Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05086692","url":"https://clinicaltrials.gov/study/NCT05086692"}],"tags":["ctgov-ingest"],"related":[],"cancers":["rcc","nsclc","sclc","colorectal","cervical"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05086692","phase":"1/2","setting":"A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors","sponsor":"Medicenna Therapeutics, Inc.","enrolled":115,"outcomes":[]},"route":"/trials/nct05086692/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}]}}